Gene type may affect how cancer drug works in patients
NCT ID NCT02680795
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 29 times
Summary
This study looked at how the cancer drug belinostat is processed in the body by people with advanced solid tumors or blood cancers. Researchers wanted to see if a person's genetic makeup (specifically the UGT1A1 gene) changes how the drug works or causes side effects. The study included 17 patients whose cancer had returned or stopped responding to treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gabrail Cancer Center Research
Canton, Ohio, 44718, United States
-
John Wayne Cancer Institute @ Providence Saint John's Health Center
Santa Monica, California, 90404, United States
-
The Oncology Institute of Hope and Innovation
Whittier, California, 90603, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.